Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
For the nine months, revenue was USD 103.21 million compared to USD 145.86 million a year ago. Net income was USD 31.45 million compared to net loss of USD 15.88 million a year ago. Basic earnings per share from continuing operations was USD 1.92 compared to USD 0.55 a year ago. Diluted earnings per share from continuing operations was USD 1.86 compared to USD 0.54 a year ago. Basic earnings per share was USD 1.82 compared to basic loss per share of USD 0.94 a year ago. Diluted earnings per share was USD 1.77 compared to diluted loss per share of USD 0.93 a year ago.